

Johan W Jonker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4272296/publications.pdf>

Version: 2024-02-01

87
papers

11,244
citations

66234

42
h-index

51492

86
g-index

90
all docs

90
docs citations

90
times ranked

11651
citing authors

#	ARTICLE	IF	CITATIONS
1	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. <i>Advanced Drug Delivery Reviews</i> , 2003, 55, 3-29.	6.6	1,259
2	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 138-153.	6.6	903
3	Nonlinear partial differential equations and applications: The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 15649-15654.	3.3	759
4	Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPAR β -Dependent Switch From Lipogenesis to Fat Oxidation. <i>Diabetes</i> , 2015, 64, 2398-2408.	0.3	734
5	Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1651-1656.	3.0	550
6	Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. <i>Nature</i> , 2011, 480, 552-556.	13.7	481
7	Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 510-515.	1.3	398
8	The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. <i>Nature Medicine</i> , 2005, 11, 127-129.	15.2	376
9	Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 2-9.	1.3	334
10	ERR β Directs and Maintains the Transition to Oxidative Metabolism in the Postnatal Heart. <i>Cell Metabolism</i> , 2007, 6, 13-24.	7.2	274
11	Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 144-152.	1.3	258
12	Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations. <i>Molecular and Cellular Biology</i> , 2003, 23, 7902-7908.	1.1	244
13	Inhibition of mTORC1 by Astrin and Stress Granules Prevents Apoptosis in Cancer Cells. <i>Cell</i> , 2013, 154, 859-874.	13.5	243
14	A PPAR β -FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. <i>Nature</i> , 2012, 485, 391-394.	13.7	240
15	Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. <i>Hepatology</i> , 2020, 72, 1864-1872.	3.6	221
16	Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene. <i>Molecular and Cellular Biology</i> , 2001, 21, 5471-5477.	1.1	220
17	The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin. <i>Molecular Pharmacology</i> , 2005, 67, 1758-1764.	1.0	203
18	Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. <i>Nature</i> , 2014, 513, 436-439.	13.7	201

#	ARTICLE	IF	CITATIONS
19	The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. <i>Cancer Research</i> , 2003, 63, 6447-52.	0.4	199
20	Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B ₂) into Milk. <i>Molecular and Cellular Biology</i> , 2007, 27, 1247-1253.	1.1	191
21	Involvement of Organic Cation Transporter 1 in the Lactic Acidosis Caused by Metformin. <i>Molecular Pharmacology</i> , 2003, 63, 844-848.	1.0	180
22	Exercise and PGC-1 α -Independent Synchronization of Type I Muscle Metabolism and Vasculature by ERR α . <i>Cell Metabolism</i> , 2011, 13, 283-293.	7.2	156
23	Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver. <i>Molecular Pharmacology</i> , 2005, 67, 1765-1771.	1.0	144
24	Malnutrition-associated liver steatosis and ATP depletion is caused by peroxisomal and mitochondrial dysfunction. <i>Journal of Hepatology</i> , 2016, 65, 1198-1208.	1.8	133
25	Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B ₁ , IQ and Trp-P-1 but also mediates their secretion into breast milk. <i>Carcinogenesis</i> , 2005, 27, 123-130.	1.3	132
26	FXR and PXR: Potential therapeutic targets in cholestasis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 130, 147-158.	1.2	127
27	Contribution of the ABC Transporters Bcrp1 and Mdr1a/1b to the Side Population Phenotype in Mammary Gland and Bone Marrow of Mice. <i>Stem Cells</i> , 2005, 23, 1059-1065.	1.4	126
28	TRANSPORT OF ANTHELMINTIC BENZIMIDAZOLE DRUGS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2). <i>Drug Metabolism and Disposition</i> , 2005, 33, 614-618.	1.7	120
29	Investigation of Efflux Transport of Dehydroepiandrosterone Sulfate and Mitoxantrone at the Mouse Blood-Brain Barrier: A Minor Role of Breast Cancer Resistance Protein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 44-52.	1.3	113
30	Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications. <i>Annals of the New York Academy of Sciences</i> , 2000, 922, 188-194.	1.8	100
31	Fibroblast Growth Factor Signaling in Metabolic Regulation. <i>Frontiers in Endocrinology</i> , 2015, 6, 193.	1.5	100
32	Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. <i>British Journal of Pharmacology</i> , 1999, 127, 43-50.	2.7	98
33	SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20021-20026.	3.3	83
34	Cystic Fibrosis-related Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 443-448.	0.9	80
35	Recent Advances in Molecular Pharmacology of the Histamine Systems: Organic Cation Transporters as a Histamine Transporter and Histamine Metabolism. <i>Journal of Pharmacological Sciences</i> , 2006, 101, 24-30.	1.1	74
36	Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. <i>Drug Metabolism and Disposition</i> , 2004, 32, 898-901.	1.7	67

#	ARTICLE	IF	CITATIONS
37	ERRÎ³ Regulates Cardiac, Gastric, and Renal Potassium Homeostasis. <i>Molecular Endocrinology</i> , 2010, 24, 299-309.	3.7	61
38	Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2288-2293.	3.3	60
39	Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8555-8560.	3.3	56
40	New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 273-293.	1.5	52
41	Dietary <i>Sargassum fusiforme</i> improves memory and reduces amyloid plaque load in an Alzheimerâ€™s disease mouse model. <i>Scientific Reports</i> , 2019, 9, 4908.	1.6	51
42	The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2020, 11, 601627.	1.5	50
43	Impaired Hepatic Vitamin A Metabolism in NAFLD Mice Leading to Vitamin A Accumulation in Hepatocytes. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 309-325.e3.	2.3	46
44	Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. <i>Current Opinion in Lipidology</i> , 2019, 30, 235-243.	1.2	40
45	Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 125-133.	1.9	40
46	P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. <i>British Journal of Cancer</i> , 2003, 89, 1776-1782.	2.9	39
47	FGF1 and insulin control lipolysis by convergent pathways. <i>Cell Metabolism</i> , 2022, 34, 171-183.e6.	7.2	36
48	Intestinal PPARÎ³ protects against diet-induced obesity, insulin resistance and dyslipidemia. <i>Scientific Reports</i> , 2017, 7, 846.	1.6	32
49	Identification of the fructose transporter GLUT5 (SLC2A5) as a novel target of nuclear receptor LXR. <i>Scientific Reports</i> , 2019, 9, 9299.	1.6	32
50	Mutations in the Vâ€™ATPase Assembly Factor VMA21 Cause a Congenital Disorder of Glycosylation With Autophagic Liver Disease. <i>Hepatology</i> , 2020, 72, 1968-1986.	3.6	32
51	Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 292, C2204-C2212.	2.1	30
52	Hepatic Farnesoid X-Receptor Isoforms Î±2 and Î±4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice. <i>PLoS ONE</i> , 2014, 9, e115028.	1.1	30
53	Lack of Improvement of Oral Absorption of ME3277 by Prodrug Formation Is Ascribed to the Intestinal Efflux Mediated by Breast Cancer Resistant Protein (BCRP/ABCG2). <i>Pharmaceutical Research</i> , 2005, 22, 613-618.	1.7	29
54	GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis. <i>Journal of Neuroscience</i> , 2017, 37, 9925-9938.	1.7	29

#	ARTICLE	IF	CITATIONS
55	IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 286-293.	0.3	26
56	Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2022, 75, 125-139.	3.6	25
57	Metabolic consequences of ileal interruption of the enterohepatic circulation of bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G619-G625.	1.6	24
58	Hepatobiliary ABC transporters: physiology, regulation and implications for disease. <i>Frontiers in Bioscience - Landmark</i> , 2009, 14, 4904.	3.0	20
59	Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice. <i>Journal of Lipid Research</i> , 2019, 60, 1562-1572.	2.0	19
60	Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 313-320.	0.3	18
61	Short-term protein restriction at advanced age stimulates FGF21 signalling, energy expenditure and browning of white adipose tissue. <i>FEBS Journal</i> , 2021, 288, 2257-2277.	2.2	18
62	Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 562-569.	1.2	17
63	Renal organic cation and nucleoside transport. <i>Biochemical Pharmacology</i> , 2002, 64, 185-190.	2.0	16
64	Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease. <i>Handbook of Experimental Pharmacology</i> , 2019, 256, 207-234.	0.9	16
65	TUB gene expression in hypothalamus and adipose tissue and its association with obesity in humans. <i>International Journal of Obesity</i> , 2018, 42, 376-383.	1.6	14
66	24(S)-Saringosterol Prevents Cognitive Decline in a Mouse Model for Alzheimer's Disease. <i>Marine Drugs</i> , 2021, 19, 190.	2.2	12
67	Potential of therapeutic bile acids in the treatment of neonatal Hyperbilirubinemia. <i>Scientific Reports</i> , 2021, 11, 11107.	1.6	12
68	Age-related susceptibility to insulin resistance arises from a combination of CPT1B decline and lipid overload. <i>BMC Biology</i> , 2021, 19, 154.	1.7	12
69	Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 293-301.	2.0	12
70	Characterization of stem cell-derived liver and intestinal organoids as a model system to study nuclear receptor biology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 687-700.	1.8	11
71	Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G404-G411.	1.6	11
72	NF- κ B p65 serine 467 phosphorylation sensitizes mice to weight gain and TNF α -or diet-induced inflammation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 1785-1798.	1.9	9

#	ARTICLE	IF	CITATIONS
73	Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 47-60.	2.3	9
74	Increased insulin sensitivity and diminished pancreatic beta-cell function in DNA repair deficient Ercc1 mice. Metabolism: Clinical and Experimental, 2021, 117, 154711.	1.5	9
75	Blue LED phototherapy in preterm infants: effects on an oxidative marker of DNA damage. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2020, 105, 628-633.	1.4	8
76	Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation. Drug Metabolism and Disposition, 2021, 49, 12-19.	1.7	8
77	Defective Lipid Droplet-Lysosome Interaction Causes Fatty Liver Disease as Evidenced by Human Mutations in TMEM199 and CCDC115. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 583-597.	2.3	8
78	LED-phototherapy does not induce oxidative DNA damage in hyperbilirubinemic Gunn rats. Pediatric Research, 2019, 85, 1041-1047.	1.1	7
79	Senescent cells in the development of cardiometabolic disease. Current Opinion in Lipidology, 2019, 30, 177-185.	1.2	7
80	The Beneficial Effects of Apical Sodium-Dependent Bile Acid Transporter Inactivation Depend on Dietary Fat Composition. Molecular Nutrition and Food Research, 2020, 64, e2000750.	1.5	7
81	Mice with a deficiency in Peroxisomal Membrane Protein 4 (PXMP4) display mild changes in hepatic lipid metabolism. Scientific Reports, 2022, 12, 2512.	1.6	7
82	Polymorphisms affecting function of the human organic cation transporter hOCT1 (SLC22A1). Pharmacogenetics and Genomics, 2002, 12, 589-590.	5.7	5
83	A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis. Molecular Metabolism, 2022, , 101472.	3.0	5
84	Inhibition of mTORC1 by Astrin and Stress Granules Prevents Apoptosis in Cancer Cells. Cell, 2013, 155, 964-966.	13.5	1
85	Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats. Pediatric Research, 2021, 89, 510-517.	1.1	1
86	PS21 - 100. A PPAR-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 170-170.	0.0	0
87	Reply to: "Impaired expression of multidrug resistance-associated protein 2 and liver damage in erythropoietic protoporphyria". Hepatology, 2016, 63, 1743-1744.	3.6	0